Cargando…

Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Purpose: Liver involvement in autosomal recessive polycystic kidney disease (ARPKD) leads to the development of portal hypertension and its complications. The aim of this study was to analyze the occurrence of the portal hypertension and its clinical course and the dynamics in patients with molecula...

Descripción completa

Detalles Bibliográficos
Autores principales: Wicher, Dorota, Grenda, Ryszard, Teisseyre, Mikołaj, Szymczak, Marek, Halat-Wolska, Paulina, Jurkiewicz, Dorota, Liebau, Max Christoph, Ciara, Elżbieta, Rydzanicz, Małgorzata, Kosińska, Joanna, Chrzanowska, Krystyna, Jankowska, Irena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690924/
https://www.ncbi.nlm.nih.gov/pubmed/33282801
http://dx.doi.org/10.3389/fped.2020.591379
_version_ 1783614180028317696
author Wicher, Dorota
Grenda, Ryszard
Teisseyre, Mikołaj
Szymczak, Marek
Halat-Wolska, Paulina
Jurkiewicz, Dorota
Liebau, Max Christoph
Ciara, Elżbieta
Rydzanicz, Małgorzata
Kosińska, Joanna
Chrzanowska, Krystyna
Jankowska, Irena
author_facet Wicher, Dorota
Grenda, Ryszard
Teisseyre, Mikołaj
Szymczak, Marek
Halat-Wolska, Paulina
Jurkiewicz, Dorota
Liebau, Max Christoph
Ciara, Elżbieta
Rydzanicz, Małgorzata
Kosińska, Joanna
Chrzanowska, Krystyna
Jankowska, Irena
author_sort Wicher, Dorota
collection PubMed
description Purpose: Liver involvement in autosomal recessive polycystic kidney disease (ARPKD) leads to the development of portal hypertension and its complications. The aim of this study was to analyze the occurrence of the portal hypertension and its clinical course and the dynamics in patients with molecularly confirmed ARPKD in a large Polish center. Moreover, the available options in diagnostics, prevention and management of portal hypertension in ARPKD will be discussed. Materials and Methods: The study group consisted of 17 patients aged 2.5–42 years. All patients had ARPKD diagnosis confirmed by molecular tests. Retrospective analysis included laboratory tests, ultrasound and endoscopic examinations, transient elastography and clinical evaluation. Results: Any symptom of portal hypertension was established in 71% of patients. Hypersplenism, splenomegaly, decreased portal flow and esophageal varices were found in 47, 59, 56, and 92% of patients, respectively. Gastrointestinal bleeding occurred in four of 17 patients. Endoscopic variceal ligation (EVL) was performed at least once in nine patients with esophageal varices. Conclusions: Portal hypertension and its complications are present in a significant percentage of ARPKD patients. They should be under the care of multidisciplinary nephrology-gastroenterology/hepatology team. Complications of portal hypertension may occur early in life. Endoscopic methods of preventing gastroesophageal bleeding, such as endoscopic variceal ligation, are effective and surgical techniques, including liver transplantation, are required rarely.
format Online
Article
Text
id pubmed-7690924
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76909242020-12-04 Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD) Wicher, Dorota Grenda, Ryszard Teisseyre, Mikołaj Szymczak, Marek Halat-Wolska, Paulina Jurkiewicz, Dorota Liebau, Max Christoph Ciara, Elżbieta Rydzanicz, Małgorzata Kosińska, Joanna Chrzanowska, Krystyna Jankowska, Irena Front Pediatr Pediatrics Purpose: Liver involvement in autosomal recessive polycystic kidney disease (ARPKD) leads to the development of portal hypertension and its complications. The aim of this study was to analyze the occurrence of the portal hypertension and its clinical course and the dynamics in patients with molecularly confirmed ARPKD in a large Polish center. Moreover, the available options in diagnostics, prevention and management of portal hypertension in ARPKD will be discussed. Materials and Methods: The study group consisted of 17 patients aged 2.5–42 years. All patients had ARPKD diagnosis confirmed by molecular tests. Retrospective analysis included laboratory tests, ultrasound and endoscopic examinations, transient elastography and clinical evaluation. Results: Any symptom of portal hypertension was established in 71% of patients. Hypersplenism, splenomegaly, decreased portal flow and esophageal varices were found in 47, 59, 56, and 92% of patients, respectively. Gastrointestinal bleeding occurred in four of 17 patients. Endoscopic variceal ligation (EVL) was performed at least once in nine patients with esophageal varices. Conclusions: Portal hypertension and its complications are present in a significant percentage of ARPKD patients. They should be under the care of multidisciplinary nephrology-gastroenterology/hepatology team. Complications of portal hypertension may occur early in life. Endoscopic methods of preventing gastroesophageal bleeding, such as endoscopic variceal ligation, are effective and surgical techniques, including liver transplantation, are required rarely. Frontiers Media S.A. 2020-11-12 /pmc/articles/PMC7690924/ /pubmed/33282801 http://dx.doi.org/10.3389/fped.2020.591379 Text en Copyright © 2020 Wicher, Grenda, Teisseyre, Szymczak, Halat-Wolska, Jurkiewicz, Liebau, Ciara, Rydzanicz, Kosińska, Chrzanowska and Jankowska. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Wicher, Dorota
Grenda, Ryszard
Teisseyre, Mikołaj
Szymczak, Marek
Halat-Wolska, Paulina
Jurkiewicz, Dorota
Liebau, Max Christoph
Ciara, Elżbieta
Rydzanicz, Małgorzata
Kosińska, Joanna
Chrzanowska, Krystyna
Jankowska, Irena
Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD)
title Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD)
title_full Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD)
title_fullStr Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD)
title_full_unstemmed Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD)
title_short Occurrence of Portal Hypertension and Its Clinical Course in Patients With Molecularly Confirmed Autosomal Recessive Polycystic Kidney Disease (ARPKD)
title_sort occurrence of portal hypertension and its clinical course in patients with molecularly confirmed autosomal recessive polycystic kidney disease (arpkd)
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690924/
https://www.ncbi.nlm.nih.gov/pubmed/33282801
http://dx.doi.org/10.3389/fped.2020.591379
work_keys_str_mv AT wicherdorota occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT grendaryszard occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT teisseyremikołaj occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT szymczakmarek occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT halatwolskapaulina occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT jurkiewiczdorota occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT liebaumaxchristoph occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT ciaraelzbieta occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT rydzaniczmałgorzata occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT kosinskajoanna occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT chrzanowskakrystyna occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd
AT jankowskairena occurrenceofportalhypertensionanditsclinicalcourseinpatientswithmolecularlyconfirmedautosomalrecessivepolycystickidneydiseasearpkd